Covid19
Adamis' shares nosedive as sole clinical-stage asset flunks COVID-19 trial – Fierce Biotech
Another COVID-19 therapy bites the dust. This time it's Adamis Pharmaceuticals' failed phase 2/3 trial for antiviral Tempol.
Another COVID-19 therapy bites the dust. This time it's Adamis Pharmaceuticals' failed phase 2/3 trial for antiviral Tempol.